KR101565185B1 - 건안증을 치료하기 위한 베타-턴 펩티도미메틱 환상 화합물 - Google Patents

건안증을 치료하기 위한 베타-턴 펩티도미메틱 환상 화합물 Download PDF

Info

Publication number
KR101565185B1
KR101565185B1 KR1020107024714A KR20107024714A KR101565185B1 KR 101565185 B1 KR101565185 B1 KR 101565185B1 KR 1020107024714 A KR1020107024714 A KR 1020107024714A KR 20107024714 A KR20107024714 A KR 20107024714A KR 101565185 B1 KR101565185 B1 KR 101565185B1
Authority
KR
South Korea
Prior art keywords
compound
group
day
rats
scopolamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107024714A
Other languages
English (en)
Korean (ko)
Other versions
KR20110010712A (ko
Inventor
가르트 쿰버리지
카렌 미로비치
테레사 라마
에이치. 우리 사라고비
Original Assignee
미메토젠 파르마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미메토젠 파르마슈티칼스 인크. filed Critical 미메토젠 파르마슈티칼스 인크.
Publication of KR20110010712A publication Critical patent/KR20110010712A/ko
Application granted granted Critical
Publication of KR101565185B1 publication Critical patent/KR101565185B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020107024714A 2008-04-04 2009-04-03 건안증을 치료하기 위한 베타-턴 펩티도미메틱 환상 화합물 Active KR101565185B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12303608P 2008-04-04 2008-04-04
US61/123,036 2008-04-04
US20887309P 2009-02-27 2009-02-27
US61/208,873 2009-02-27

Publications (2)

Publication Number Publication Date
KR20110010712A KR20110010712A (ko) 2011-02-07
KR101565185B1 true KR101565185B1 (ko) 2015-11-02

Family

ID=40897413

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107024714A Active KR101565185B1 (ko) 2008-04-04 2009-04-03 건안증을 치료하기 위한 베타-턴 펩티도미메틱 환상 화합물

Country Status (9)

Country Link
US (4) US8293713B2 (enExample)
EP (1) EP2271337B1 (enExample)
JP (2) JP5480242B2 (enExample)
KR (1) KR101565185B1 (enExample)
CN (1) CN102046166B (enExample)
AU (1) AU2009232352B2 (enExample)
CA (1) CA2720141C (enExample)
ES (1) ES2521515T3 (enExample)
WO (1) WO2009123761A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102046166B (zh) 2008-04-04 2012-10-17 米梅托根药物公司 用于治疗干眼症的β-转角模拟肽环状化合物
JP6248103B2 (ja) * 2012-06-22 2017-12-13 ミメトゲン ファーマシュウティカルズ インコーポレイテッドＭｉｍｅｔｏｇｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． β−ターン環式ペプチド模倣化合物の合成
KR20150004652A (ko) 2013-07-03 2015-01-13 삼성디스플레이 주식회사 표시 패널, 이를 포함하는 표시 장치 및 이를 이용하는 영상 표시 방법
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
EP3244851B1 (en) 2015-01-12 2024-10-16 Bausch + Lomb Ireland Limited Micro-droplet delivery device
KR20170135862A (ko) 2015-04-10 2017-12-08 켄달리온 테라퓨틱스 인코포레이티드 교체 가능한 앰플을 갖는 압전 디스펜서
CA2991661A1 (en) * 2015-07-09 2017-01-12 Mimetogen Pharmaceuticals, Inc. Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
KR101718733B1 (ko) 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제
US10799447B2 (en) 2016-03-04 2020-10-13 James M. Rynerson Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation
KR102412086B1 (ko) 2017-01-20 2022-06-22 켄달리온 테라퓨틱스 인코포레이티드 압전 유체 분배기
CN111712219A (zh) 2017-12-08 2020-09-25 科达莱昂治疗公司 流体递送对准系统
CN110092799B (zh) * 2018-01-29 2021-11-12 广州丹康医药生物有限公司 一种环状化合物、其制备方法和应用
US20190314198A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
EP3817696B8 (en) 2018-07-03 2024-12-11 Bausch + Lomb Ireland Limited Topical ocular delivery devices
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US11925577B2 (en) 2020-04-17 2024-03-12 Bausch + Lomb Ireland Limted Hydrodynamically actuated preservative free dispensing system
WO2021212038A1 (en) 2020-04-17 2021-10-21 Kedalion Therapeutics, Inc. Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
JP2024520670A (ja) * 2021-06-02 2024-05-24 ザ テキサス エーアンドエム ユニヴァーシティ システム Ｔｒｋ受容体の選択的小分子アゴニスト及び部分アゴニスト
KR20240108412A (ko) * 2021-10-20 2024-07-09 스텔스 바이오테라퓨틱스 인코포레이티드 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물
WO2023069255A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052843A1 (en) 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8917217D0 (en) * 1989-07-27 1989-09-13 Smith & Nephew Ophthalmic compositions
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
CN1283997A (zh) * 1997-12-22 2001-02-14 人类基因组科学公司 角质形成细胞生长因子－2制剂
JP2001064198A (ja) * 1999-08-24 2001-03-13 Teika Seiyaku Kk 角膜疾患治療剤
EP1734052B1 (en) * 2005-06-13 2009-02-18 Primm S.R.L. Heterodimeric peptide compounds displaying NGF activity and their use to treat neurodegenerative disorders
EP1921087A1 (en) 2006-11-10 2008-05-14 Primm S.R.L. Process for the preparation of cyclic peptides
JP5576659B2 (ja) * 2006-12-05 2014-08-20 ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング／ マギル ユニバーシティ Ｔｒｋレセプター調節因子の使用方法
CN102046166B (zh) 2008-04-04 2012-10-17 米梅托根药物公司 用于治疗干眼症的β-转角模拟肽环状化合物
CA2752891C (en) * 2009-02-27 2018-08-21 Mimetogen Pharmaceuticals Inc. Peptidomimetic cyclic compounds for treating retinitis pigmentosa
JP6248103B2 (ja) * 2012-06-22 2017-12-13 ミメトゲン ファーマシュウティカルズ インコーポレイテッドＭｉｍｅｔｏｇｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． β−ターン環式ペプチド模倣化合物の合成

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052843A1 (en) 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS

Also Published As

Publication number Publication date
US8293713B2 (en) 2012-10-23
CN102046166A (zh) 2011-05-04
CN102046166B (zh) 2012-10-17
US20110105410A1 (en) 2011-05-05
WO2009123761A1 (en) 2009-10-08
US8748391B2 (en) 2014-06-10
US9156882B2 (en) 2015-10-13
EP2271337A1 (en) 2011-01-12
EP2271337B1 (en) 2014-09-03
CA2720141A1 (en) 2009-10-08
AU2009232352A1 (en) 2009-10-08
HK1152898A1 (en) 2012-03-16
ES2521515T3 (es) 2014-11-12
US20140274910A1 (en) 2014-09-18
JP2011516477A (ja) 2011-05-26
JP2014080447A (ja) 2014-05-08
US20160082072A1 (en) 2016-03-24
AU2009232352B2 (en) 2013-09-05
JP5480242B2 (ja) 2014-04-23
KR20110010712A (ko) 2011-02-07
US20120322747A1 (en) 2012-12-20
CA2720141C (en) 2014-01-28
US9707267B2 (en) 2017-07-18
JP5870348B2 (ja) 2016-02-24

Similar Documents

Publication Publication Date Title
KR101565185B1 (ko) 건안증을 치료하기 위한 베타-턴 펩티도미메틱 환상 화합물
US20120142591A1 (en) Method of treating intraoccular tissue pathologies with nerve growth factor
IL259562A (en) Aminophosphinic derivatives for preventing and treating eye pain
AU1506600A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
IT9020968A1 (it) Composto farmaceutico a base di un antocianidina per il trattamento di malattie oftalmiche
US11998571B2 (en) Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
AU2010217889B2 (en) Peptidomimetic cyclic compounds for treating retinitis pigmentosa
WO2010107069A1 (ja) アミノ酸含有眼科用組成物
US20240043396A1 (en) Methods of treating ocular fibrotic pathologies
HK1152898B (en) Beta-turn peptidomimetic cyclic compounds for treating dry eye
RU2442582C2 (ru) Стимулятор образования нейритов
WO2014115011A1 (en) Compositions for use in treating eye disorders using opioid receptor antagonists
JPH1180000A (ja) 翼状片予防・治療剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20181018

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20191023

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11